ZEJULA is a treatment option for women with late-line advanced ovarian cancer
ZEJULA is indicated for three groups of people with ovarian cancer, including as a treatment for late-line ovarian cancer, discussed here.
ZEJULA may be an option for you if you’ve had at least 3 prior chemotherapy regimens and have tumors with
- a certain BRCA gene mutation, or
- gene mutation problems and have progressed more than 6 months after your last treatment with platinum-based chemotherapy
- Your healthcare provider will perform a test to make sure that ZEJULA is right for you
QUADRA is a clinical trial that studied how well ZEJULA worked and how safe it was in women with ovarian cancer, including epithelial ovarian, fallopian tube, or primary peritoneal cancer, with a positive test result for certain genetic characteristics called HRD.*
The HRD-positive group included women with an inherited BRCA† mutation, as well as those with gene mutation problems who had progressed more than 6 months after their last treatment with platinum-based chemotherapy. All women had been treated with at least 3 prior lines of chemotherapy. In the trial, women only received treatment with ZEJULA. The study was designed to measure how well women living with advanced ovarian cancer responded to treatment with ZEJULA.
*HRD, or homologous recombination deficiency, occurs when cells have difficulty repairing themselves and appears in about 50% of women with ovarian cancer.
†BRCA refers to a set of genes called BRCA1 and BRCA2. Mutations in BRCA genes increase a woman’s risk of developing ovarian cancer, but having a BRCA mutation does not mean a woman will develop ovarian cancer. BRCA mutations can be inherited, or passed from parents to their children.
Half of the women who responded to ZEJULA had a response that lasted longer than 8 months
Response describes how well a cancer reacts to treatment.‡ The duration of response is the time from the cancer responding to the treatment until the cancer gets worse. Median is the middle number in a set of data, also called the midpoint.
Received ZEJULA (98 women)
months median duration of response with ZEJULA treatment
‡If some, but not all, of the cancer disappears, it is a partial response. If there are no remaining clinical signs of cancer, it is considered a complete response, although this does not always mean that the cancer has been cured.
24% of women had some of their cancer disappear
In the QUADRA trial, 24% of women responded to ZEJULA, meaning their tumors shrank in size.